The offering adds ~4.3M shares (potentially ~5.0M with over-allotment) to a micro-cap float, creating immediate dilution. Monitor for any subsequent operational updates or revenue milestones that could offset the dilutive impact; the FDA clearance for MEDIFLY Maggots is a potential catalyst but no commercialization timeline was provided.
Price Chart
Executive Summary
Cuprina closed a public offering of 4,322,489 Class A Ordinary Shares at $1.15/share, raising ~$4.97M in gross proceeds. The underwriter has a 45-day option for an additional 648,373 shares (15% over-allotment), which would bring total proceeds to ~$5.72M. Proceeds are earmarked for expansion, R&D, market entry, and working capital.
Key Financial Metrics
Key Facts
- Closed public offering of 4,322,489 Class A Ordinary Shares at $1.15/share
- Gross proceeds of approximately $4.97 million
- Underwriter granted 45-day option to purchase up to 648,373 additional shares (15% over-allotment)
- If over-allotment exercised, total gross proceeds would be ~$5.72 million
- Net proceeds to be used for expansion, R&D, new markets, brand awareness, equipment, and working capital
- Offering conducted under SEC-registered Form F-1 (File No: 333-297299), declared effective September 15, 2026
- Sole book-running manager: R. F. Lafferty & Co., Inc.
- Company received FDA 510(k) clearance for MEDIFLY Maggots™ in June 2026
Financial Impact
Gross proceeds of $4.97M (or $5.72M with over-allotment) represent a dilutive capital raise for a micro-cap company; no revenue or earnings figures disclosed.
Risk Factors
- Dilution from the offering may pressure the stock price in the near term
- No revenue or earnings data disclosed; company remains pre-revenue or early-stage
- Use of proceeds is broad and non-specific, raising execution risk
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364445 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $1.93 $1.85 | ▲ +4.15% | ▲ +4.22% | $1.85 (+4.15%) |
Oct 2, 2026 25d ago | 6-K | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.85 (−23.55%) |
Oct 2, 2026 25d ago | Press Release | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.85 (−23.55%) |
Sep 29, 2026 28d ago | 6-K | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.85 (+18.86%) |
Sep 29, 2026 28d ago | Press Release | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.85 (+18.86%) |
Sep 18, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 17, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 17, 2026 5w ago | Press Release | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 16, 2026 5w ago | 424B4 | $1.60 $1.88 | ▼ −17.50% | ▼ −15.68% | $1.85 (−15.63%) |
Sep 16, 2026 5w ago | EFFECT | $1.60 $1.88 | ▼ −17.50% | ▼ −14.94% | $1.85 (−15.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers